AbbVie Stock Will $300: Timing and Risks to Watch
AbbVie’s Q1 2026 results show strong immunology growth even as biosimilar challenges weigh on revenue. Analysts debat...
Determine which funds deliver the best annual risk-adjusted returns and how they stack up. Compare contenders to pick winners.
28,456 articlesAbbVie’s Q1 2026 results show strong immunology growth even as biosimilar challenges weigh on revenue. Analysts debat...
Inflation data and hawkish Fed messaging dominate markets this week as investors weigh mortgage rates and the path of...
Nvidia Chief Executive Jensen Huang indicated the company plans to cap its OpenAI investment well below $100 billion ...
Barclays boosts its view on Charles Schwab after the firm guides for higher 2026 revenue and reports stronger Q1 resu...
As July 1 approaches, caps on federal student loan borrowing under the One Big Beautiful Bill Act threaten graduate a...
Dell Technologies has surged on AI demand, pushing year-to-date gains toward 230% as investors bet the hardware giant...
The February 2026 jobs report shows a surprising payroll pullback, with 92,000 fewer positions. Unemployment rose to ...
A suburban district is debating whether to curb or ban classroom devices as a growing number of parents push back aga...
U.S. households show mounting stress as debt payments rise, savings shrink, and spending cools. Five indicators point...
Suze Orman explains why wills alone can fail in blended families and offers steps to align trusts and beneficiary des...
Binance's XRP reserves fell to about 2.61 billion tokens, a trough not seen since February. XRP price briefly rebound...
A Texas Senate hopeful rides viral videos to a Democratic nomination, while Republicans mine his social media history...